About Us

Our company

Cape Biologix Technologies, a subsidiary of Cape Bio Pharms, utilizes plant-based expression platforms to improve the health and well-being of people and animals. We started in 2020 with the mission to contribute to global biosecurity through manufacturing high quality plant-based proteins that are accessible and economical.  

Our transient plant-based expression platform provides a compelling competitive alternative to traditional expression platforms through its superior speed, quality, flexibility, scalability, and sustainability.

As a subsidiary of Cape Bio Pharms we are very fortunate to have several strategic partners around the world supporting us.

Partners

VALUES

Our Values

agsdix-sout-heart

Be Human

We strive to show up authentically and build safe and productive relationships with our colleagues and partners.

Persevere With Purpose

We keep our eyes on the prize when the going gets tough.

Hit The Target

In everything we do we aim to achieve the right results, every time

History

Our History

Cape Biologix Technologies, since being founded in 2022, has established itself as a pioneer in plant-made recombinant protein manufacture after rapidly upscaling its facilities and expanding its catalogue of plant-made recombinant proteins.

 

 

2018

Cape Bio Pharms was founded in Cape Town, South Africa.

2018

Cape Bio Pharms commenced construction of plant-based research and development facility in Cape Town.

2019

Cape Bio Pharms successfully developed more than 40 proof of concept plant-based proteins.

2020

Cape Biologix Technologies was founded as the production subsidiary of Cape Bio Pharms.

2020

Cape Biologix Technologies began working with several financial institutions to realize our mission of having multiple cGMP plant-based production facilities in Africa for the manufacture of diagnostic, biosimilar, therapeutic, and vaccine proteins.

2021

Cape Biologix Technologies rapidly launched a suite of SARS-CoV-2 proteins into the market for use in lateral flow test kits.

2021

Cape Biologix Technologies completed the construction of the Cape Town production facility.

2022

Cape Biologix Technologies began the development of over 30 research reagents for use in several indications such as oncology, cell culture, immunology, and recombinant protein expression.

We are grateful to have highly experienced industry leaders in our executive team

Executive Team

Kobus Lindeque

CEO / COO

Kobus Lindeque was appointed as CEO in July 2022. He is one of South Africa’s most respected biotechnology leaders, having held Managing Director positions in some of the largest biotechnology companies in the world, namely: Monsanto (Africa), Kapa Biosystems (Roche), Afrikelp Holdings, and Syngenta Seed Company.

Belinda Shaw

Executive Chair / Founder / Investor Relations and Strategic Projects

Belinda Shaw founded Cape Bio Pharms in 2018. Her entrepreneurial spirit inspired her to commercialize our transient plant-based expression platform in service of contributing to global biosecurity. She previously spent over 20 years running her own businesses providing video production services for local and international corporate clients focusing on strategic communications as well as investigative video journalism for local and international news and documentary channels.

Lynn Scheel – CFO

CFO

Lynn Scheel is both a Certified Professional Accountant and a Certified Internal Auditor. Since joining in 2020 as out Financial Manager, Lynn was appointed as Financial Director in April 2022. Lynn has held executive financial positions in multinational-companies such as De Heus Animal Feed, Insight Digital and DHL Supply Chain. She has extensive experience in the manufacturing, logistics and service industries, franchising and co-operative structures.

Prof. Edward (Ed) Rybicki

Scientific Advisor

Professor Ed Rybicki, currently the Director of the University of Cape Town’s Biopharming Research Unit (BRU), is one of the world’s foremost experts on biopharming – using plant expression systems as platforms for the production of recombinant proteins. He has authored or co-authored over 120 articles and 19 reviews in peer-reviewed journals and about 20 book chapters, as well as a number of popular or opinion articles and conference report-backs in journals. A comprehensive and up-to-date list is available via Google Scholar citations.

Sign up for our newsletter

Click Here